standard care – Page 16 – Communicable Diseases Research

Acute Peritoneal Dialysis During the COVID-19 Pandemic at Bellevue Hospital in New York City

Observational Study

Published on 2020-10-162022-10-05
Journal: Kidney360 [Category] SARS, 임상,

Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study

COVID-19 치료의 하이드록시클로로퀸: 다기관 무작위 통제 연구

Articles

Published on 2020-10-142022-08-09
Journal: The American Journal of Tropical Medicine and Hygi [Category] MERS, SARS, 임상,

[키워드] added Administered age and gender baseline characteristics benefit conducted control arm control group Controlled Controlled trial COVID-19 pandemic COVID-19 patients death decrease decreased mortality develop diagnosis of COVID-19 did not reduce died effective Efficacy evaluate exponential growth growth HCQ Hydroxychloroquine Informed consent Laboratory parameters Logistic regression analysis mechanical ventilation mortality rate mortality rates multicenter no significant difference not differ overall mortality Patient patients with COVID-19 primary endpoint primary endpoints Randomized Randomized controlled trial significantly standard care therapy Treatment two group two groups Univariate logistic regression analysis university hospital Ventilation
[DOI] 10.4269/ajtmh.20-0873 PMC 바로가기 [Article Type] Articles

The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis

Review Article

Published on 2020-10-132022-10-31
Journal: Canadian Respiratory Journal [Category] COVID-19, MERS, SARS,

[키워드] absolute increase acute respiratory syndrome Admission adverse effect adverse effects Alter Analysis bioRxiv caused Characteristics Cochrane Central Combination control group coronavirus coronavirus disease COVID-19 COVID‐19 Disease progression Efficacy estimates Evidence extraction generate global efforts greater HCQ higher risk Hydroxychloroquine ICU admission Inconclusive independent intensive care investigator medication medRxiv Meta-analysis Mortality no difference not different pandemic participant Patient patients treated patients with COVID-19 Prevalence public health QTc QTC prolongation review risk SARS-CoV-2 searched Selection single-arm Source standard care synthesis systematic review Treatment Web of Science
[DOI] 10.1155/2020/4312519 PMC 바로가기 [Article Type] Review Article

Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report

Research Article

Published on 2020-10-052022-11-01
Journal: Journal of medical virology [Category] COVID-19, MERS, SARS,

[키워드] 95% confidence interval acute respiratory syndrome addition adjusted hazard ratio Administered Admission Adverse age clinical benefits Cohort convalescent plasma Convalescent plasma therapy coronavirus coronavirus disease COVID‐19 COVID‐19 patient COVID‐19 Critical Donor event first positive group Influenza intensive care interquartile range invasive ventilation IQR majority median Mortality not significantly different onset of symptom outcome Passive immunotherapy Patient PCR plasma polymerase chain preliminary report primary endpoint reduced required Respiratory Support Result retrospective SARS‐CoV‐2 SARS‐CoV‐2 severe coronavirus disease significantly standard care study groups the primary endpoint Treatment Trial two groups viral clearance
[DOI] 10.1002/jmv.26537 PMC 바로가기 [Article Type] Research Article

Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19

COVID-19에 대한 비교 임상 연구에서 치료 효과를 평가하기 위한 적절한 종료점 선택

Article

Published on 2020-10-012022-09-11
Journal: Contemporary clinical trials [Category] SARS, 임상, 치료법,

Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19

Covid-19에 걸린 중환자에게 회복기 혈장을 초기에 동정적으로 사용하여 얻은 교훈

Article

Published on 2020-10-012022-09-12
Journal: Transfusion [Category] Coronavirus, SARS, 진단,

Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

COVID-19 치료를 위한 중재: 메타 분석 및 시험 순차 분석을 통한 살아있는 체계적인 검토(The LIVING Project)

Research Article

Published on 2020-09-172022-08-13
Journal: PLoS Medicine [Category] Biochemistry, COVID-19, SARS,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus Admission adverse event adverse events aggregate data meta-analyses all age group all age groups all-cause mortality assessment caused certainty certainty of evidence Clinical effect Clinical research Clinical significance clinical trials Cochrane guidelines Comparisons conducted convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients database development Dexamethasone driven by Effect Evidence evidence of experimental intervention Families GRADE high risk Hydroxychloroquine individual patient data meta-analyses individuals Infection intensive care International Intervention Intervention effects item Juul lack life Lopinavir Lopinavir–ritonavir mechanical ventilation meta-analyses Meta-analysis Network meta-analysis no effect no effects no evidence of nonserious adverse event nonserious adverse events on mechanical ventilation outbreak outcome outcomes participant Participants Patient patient data paucity of data performed Placebo Primary outcomes Quality of life random errors random-effects meta-analyses randomized clinical trial randomized clinical trials rapidly spreading disease rate ratio reduce reduced reducing Remdesivir renal replacement therapy replacement therapy Reporting Research researcher respiratory Respiratory failure review risk risk of bia risk of death risk ratio Ritonavir SARS-CoV-2 searched secondary Secondary outcomes Serious Adverse Event Serious Adverse Events severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 single trial single trial randomizing Sophie Spread standard care statistically significant systematic review systematic reviews Treatment treatment for COVID-19 treatment intervention treatment of COVID-19 treatments for COVID-19 treatments of COVID-19 Trial Trial methodology trial randomizing trial sequential analyses trial sequential analysis website with COVID-19
[DOI] 10.1371/journal.pmed.1003293 PMC 바로가기 [Article Type] Research Article

Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients: A structured summary of a protocol for a randomised, controlled, clinical trial

Letter

Published on 2020-09-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Acacia addition agent Anti-inflammatory Arabic assigned assistant baseline baseline value blind change Clinical guidelines clinical trial computer-generated conducted Control COVID COVID 19 COVID 19 patient COVID-19 COVID-19 patients CRP Cytokines Date death diagnosed dissemination Efficacy element eligible patient Factor Gender group groups Gum Gum Arabic Hospital admission IL10 IL6 IL8 immunomodulation immunomodulatory independent Intervention Local mortality rate number objective outcome parallel-group participant Patient patients PCR Pectin phase Placebo placebo-controlled clinical trial Potential Prospective protocol provided random randomised randomised controlled trial randomization Randomized Randomly Real-time PCR receive Research response role Sample size secondary sequence seropositive Soba standard care state status TNFα Treatment Trial Tumor Two-arm university Version Viral load website
[DOI] 10.1186/s13063-020-04707-2 PMC 바로가기 [Article Type] Letter

Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis

Review article

Published on 2020-09-012022-10-05
Journal: Journal of integrative medicine [Category] SARS, 신약개발,

[키워드] 95% CI 95% confidence interval Adults adverse event adverse events Analysis C-reactive protein Care changes in China Chinese Chinese herbal medicine CHM Cochrane Library collected Computed tomography contagious Continuous control group Controlled trial Course COVID-19 COVID-19 cases criteria CRP current database disease evaluator Evidence Follow-up Google Scholar hazard ratio help IMPROVE Inflammatory inflammatory markers information Infrastructure life-threatening lung CT scan marker Meta-analysis New coronavirus objective Odds ratio outcome Participants Patient peer-reviewed Pneumonia Primary outcome Randomized controlled trial RCT RCTs Result risk risk of bia SARS-CoV-2 screened searched secondary SMD standard care standardized mean difference Study design Symptom systematic review therapy time-to-event analysis Traditional Chinese medicine treat Treatment treatment group Treatment outcome was used were expressed were recorded
[DOI] 10.1016/j.joim.2020.07.008 [Article Type] Review article

Immunosuppressive Drugs and COVID-19: A Review

Pharmacology

Published on 2020-08-282022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] “cytokine storm” acute respiratory syndrome analogue ARDS calcineurin inhibitors case-control study caused clinical clinical trial cohort study concerning control group coronavirus Coronavirus disease 2019 Corticosteroid Corticosteroids COVID-19 detrimental drug Effect Evidence Host immune response Human IL-6 inhibitors immunosuppressive drug immunosuppressive drugs In-vitro indication infection with SARS-CoV-2 inhibit inhibitory effect initial mechanical ventilation MERS-CoV Middle East Mortality mTOR inhibitor mTOR inhibitors multiorgan failure mycophenolic acid observational study overshoot pandemic patients with COVID-19 positive result Prevent Randomized controlled trial RCTs reduce mortality Registered respiratory syndrome coronavirus Result review risk of bia SARS-CoV SARS-CoV-2 SARS-CoV-2 replication standard care Study protocol Tocilizumab viral replication
[DOI] 10.3389/fphar.2020.01333 PMC 바로가기 [Article Type] Pharmacology